Home/Pipeline/INV-202 (Oral & LAI)

INV-202 (Oral & LAI)

Major Depressive Disorder (MDD)

PreclinicalDiscovery

Key Facts

Indication

Major Depressive Disorder (MDD)

Phase

Preclinical

Status

Discovery

Company

Indivior

About Indivior

Indivior is a publicly traded, revenue-generating biopharmaceutical company dedicated to addressing substance use disorders and serious mental illnesses. A pioneer in addiction medicine, its strategy is anchored by its market-leading SUBLOCADE® (monthly buprenorphine injection) and a pipeline extending its long-acting platform into schizophrenia and depression. The company faces significant risks from ongoing legal liabilities, generic competition, and pipeline execution, but its U.S. relocation, focused commercial execution, and potential new product launches provide a pathway for sustained growth in a critical therapeutic area.

View full company profile

Therapeutic Areas

Substance Use Disorder Opioid Use Disorder Schizophrenia Mental Illness

Other Major Depressive Disorder (MDD) Drugs

Drug	Company	Phase	Status
AL001	Alzamend Neuro	Preclinical	Research
Deep TMS (H1 Coil)	BrainsWay	FDA Cleared	Commercial
EXXUA™ (gepirone ER)	Aytu BioPharma	Commercial	Launched
Gepirone ER	Fabre-Kramer Pharmaceuticals	NDA Submitted	Active
Exablate Neuro	Insightec	Clinical Trial	Active
BrightKaire Platform for Depression	NeuroKaire	Pre-clinical	Active
Tyemvers (CKDB-501)	Healis Therapeutics	Pre-clinical	Active
VENTURA-7	New Hope Clinical Research	Phase 2/3	Active
DT-101	Draig Therapeutics	Phase 2	Active
Major Depressive Disorder Program	Actipulse Neuroscience	Phase 3	Active
Flow tDCS Headset & App	Flow Neuroscience	Approved	Active
Mood Disorders Biomarker Services	The Siesta Group	Service Offering	Active